OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Neutralizing antibodies to SARS‐CoV‐2 Omicron variant after third mRNA vaccination in health care workers and elderly subjects
Anu Haveri, Anna Solastie, Nina Ekström, et al.
European Journal of Immunology (2022) Vol. 52, Iss. 5, pp. 816-824
Open Access | Times Cited: 39

Showing 26-50 of 39 citing articles:

Robust immunogenicity of a third BNT162b2 vaccination against SARS-CoV-2 Omicron variant in a naïve New Zealand cohort
Brittany Lavender, Caitlin Hooker, Chris Frampton, et al.
Vaccine (2023) Vol. 41, Iss. 38, pp. 5535-5544
Open Access | Times Cited: 2

Impaired immunity and high attack rates caused by SARS‐CoV‐2 variants among vaccinated long‐term care facility residents
Dorothée Obach, Anna Solastie, Oona Liedes, et al.
Immunity Inflammation and Disease (2022) Vol. 10, Iss. 9
Open Access | Times Cited: 4

Age-Related Differences in Neutralizing Antibody Responses against SARS-CoV-2 Delta and Omicron Variants in 151 SARS-CoV-2-Naïve Metropolitan Residents Boosted with BNT162b2
Beomki Lee, Go Eun Bae, In Hwa Jeong, et al.
The Journal of Applied Laboratory Medicine (2024) Vol. 9, Iss. 4, pp. 741-751
Closed Access

The Predictors of COVID-19 Immunogenicity Elicited by Vaccines Against SARS-CoV-2 in Stem Cell Transplant Recipients
Umran Elbahr, Hakan Erdem, Handan Ankaralı, et al.
Flora the Journal of Infectious Diseases and Clinical Microbiology (2024) Vol. 29, Iss. 2, pp. 259-268
Open Access

Evaluation of Tembusu Virus Single-Round Infectious Particle as Vaccine vector in chickens
Libin Chen, Zhe Liu, Junqin Zhang, et al.
Veterinary Microbiology (2024) Vol. 298, pp. 110270-110270
Closed Access

Bovine milk glycoproteins inhibit SARS-CoV-2 and influenza virus co-infection
Hanjie Yu, Wentian Chen, Jian Shu, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1

Evolution of Acquired Humoral Immunity after Full Vaccination against SARS-CoV-2. IgG Levels in Healthcare Workers at 6 and 9 Months
María Victoria Delicado Useros, Esther Navarro-Rodenas, Indalecio Miguel Sánchez Onrubia, et al.
World Journal of Vaccines (2023) Vol. 13, Iss. 02, pp. 13-32
Open Access | Times Cited: 1

Hybrid immunity improves the immune response after fourth Covid-19 vaccine dose in individuals with medical conditions predisposing to severe Covid-19
Nina Ekström, Tuija Leino, Aapo Juutinen, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1

Strong neutralizing antibody responses to SARS-CoV-2 variants following a single vaccine dose in subjects with previous SARS-CoV-2 infection
Nina Ekström, Anu Haveri, Anna Solastie, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 1

Antibody titer 6 months after the third dose of COVID-19 mRNA vaccination
Rikei Kozakai, Susumu Suzuki, Kuniko Hoshi, et al.
Journal of Laboratory Medicine (2022) Vol. 47, Iss. 1, pp. 41-45
Open Access | Times Cited: 1

Robust immunogenicity of a third BNT162b2 vaccination against SARS-CoV-2 Omicron variant in a naïve New Zealand cohort
Brittany Lavender, Caitlin Hooker, Chris Frampton, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access

Clinical and laboratory considerations: determining an antibody-based composite correlate of risk for reinfection with SARS-CoV-2 or severe COVID-19
Stefan Holdenrieder, Carlos Eduardo dos Santos Ferreira, Jacques Izopet, et al.
Frontiers in Public Health (2023) Vol. 11
Open Access

Persistence of Neutralizing Antibodies and Clinical Protection up to 12 Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection in the Elderly
Rocco Collarino, Christelle Vauloup‐Fellous, Aude Allemang-Trivalle, et al.
Open Forum Infectious Diseases (2022) Vol. 9, Iss. 11
Open Access

Previous Page - Page 2

Scroll to top